Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Date:6/27/2008

enidate or other ingredients in CONCERTA(R); significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under six years of age should not take CONCERTA(R).

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA(R).

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA(R) does not adversely affect your ability to engage in such activities.

The most common adverse reaction (> 5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Visit http://www.concerta.net/concerta/pages/full.jsp for complete prescribing information.

About McNeil Pediatrics

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. McNeil Pediatrics markets CONCERTA(R) for the treatment of children, adolescents and adults with ADHD in the United States. McNeil Pediatrics continues
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... 4, 2011 InterMune, Inc. (NASDAQ: ITMN ) ... President of InterMune, will present at the Bank of America ... on May 11, 2011, at 1:00 p.m. PDT.   ... investors and other interested parties may log on to the ...
... a letter from Nicusa Capital urging BioClinica (Nasdaq: BIOC ... from incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy: ... Chairman of the Board BioClinica, Inc. 826 Newtown-Yardley Rd. Newtown, PA ... of BioClinica: As of May 4, 2011, Nicusa owns ...
... Inc. (Nasdaq: NXTM ), a leading manufacturer ... the first quarter of 2011 ended March  31, 2011, ... guidance range. (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO) Net ... to a record $50.6 million compared with revenue of ...
Cached Biology Technology:This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 2This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 3This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 4This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 5NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 2NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 3NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 4NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 5NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 6NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 7
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (June 21, 2012) Autism Speaks, the world,s leading ... of new research grants totaling nearly $2.9 million in ... extraordinarily proud of Autism Speaks, not only for funding ... avenues to understanding autism," said Autism Speaks Co-founder Bob ...
... ocean infrastructure development to tap energy sources such as ... pile driving, the practice of pounding long, hollow steel ... energy turbines and other structures. But pile driving creates ... marine animals., Many scientists and regulators have assumed that ...
... world are preparing to address the urgent need to ... biodiversity. The Global Biodiversity Informatics Conference (GBIC) will ... and policy in Copenhagen, Denmark from 2-4 July. ... strategy and roadmap to make best use of the ...
Cached Biology News:Autism Speaks awards nearly $2.9 million to fund autism research 2Autism Speaks awards nearly $2.9 million to fund autism research 3Autism Speaks awards nearly $2.9 million to fund autism research 4Turning down the dial: Ocean energy development with less sound 2Turning down the dial: Ocean energy development with less sound 3Turning down the dial: Ocean energy development with less sound 4A new vision for harnessing data about life on Earth 2
Recorder REC-111 single-channel, 1. Category: Chromatography Systems & Accessories, Systems....
... for when you need to make your strain ... efficiency. Our services for preparing competent cells are ... custom competent cell service offers: ... Fast turnaround Quality control performance testing ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
Argon Calibration Source...
Biology Products: